july 2025

De-risking cell and gene therapies by leveraging a proven workhorse technology in new ways

Team ViroCell believes that innovation doesn’t always require new discoveries. Sometimes, it’s about combining proven elements to address ongoing challenges more safely, precisely, and efficiently.

In our latest article, CSO Farzin Farzaneh, Ph.D. and VP of Corporate Development & Strategy Nicholas Ostrout, Ph.D. reveal how programmable lentiviral vectors, titer-boosting additives, and non-integrating lentiviral platforms are reshaping what’s possible in gene therapy.

• Developing programmable, tissue-specific lentiviral vectors to minimize off-target effects with constitutive expression

• Expand lentiviral vector applications with precision targeting and episomal maintenance

• Boost yield without scaling bioreactors

Whether you're advancing in vivo CAR-T therapies, rare disease treatments, or next-generation delivery systems, this piece offers a look at the future of viral vectors, targeted by design, and built for clinical reality.